ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

Completed · Phase 3

Conditions studied: Coronary Artery Disease

In brief

Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.

Key facts

Study ID

NCT00208299

Run by

Gilead Sciences

People needed

1231

Starts

2003-10-01

Expected to finish

2006-08-01

Last updated by the study team

2009-11-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Referred for a clinically indicated pharmacological stress SPECT myocardial perfusion imaging study

You may not qualify if…

• Any condition precluding the safe administration of Adenoscan for a SPECT myocardial perfusion imaging study
• Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control

Where it is running

• Multiple study locations (see Central Contact); CV Therapeutics, Inc. — Palo Alto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.